Goldman Sachs
AXDX

Goldman Sachs’s Accelerate Diagnostics AXDX Stock Holding History

Goldman Sachs’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,000
Closed -$774K – 7269
2015
Q2 		$774K Buy
+3,000
New +$716K ﹤0.01% 4769
2015
Q1 		– Sell
-740
Closed -$142K – 7069
2014
Q4 		$142K Buy
+740
New +$158K ﹤0.01% 6393

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Goldman Sachs's AXDX Position: Q1 2023 in Review

Goldman Sachs sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 3,887 shares — an estimated $27.4K sold.

Goldman Sachs first reported a position in AXDX in Q2 2013 and held it in 36 quarters. The position peaked at $4.6M in Q1 2014. 67 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

  • Goldman Sachs reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 3,887 Accelerate Diagnostics shares in Q1 2023, an estimated $27.4K.
  • Goldman Sachs first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 36 quarters.
  • Goldman Sachs's Accelerate Diagnostics position peaked at $4.6M in Q1 2014.
  • 67 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.